Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06410677
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-13
First Post:
2024-05-02
Brief Title:
Changhai Multimodal Esophageal Cancer Cohort
Sponsor:
Wangluowei
Organization:
Changhai Hospital
Study Overview
Official Title:
Prediction of Immune Infiltration Level and Immunotherapy Efficacy of Esophageal Squamous Cell Carcinoma Based on Multimodal Deep Learning
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CMECC
Brief Summary:
The burden of esophageal squamous cell carcinoma ESCC in China is substantial with 85 of the cancers being in the progressive stage The treatment for advanced ESCC are extremely limited and immunotherapy represented by PD-1 inhibitors has demonstrated a promising application potential However the effectiveness of PD-1 inhibitors varies significantly among patients with different types of ESCC and currently there is no effective method to predict the response to PD-1 inhibitors In this study investigators aim to construct a multimodal deep learning-based model to predict the level of immune infiltration and the efficacy of immunotherapy for ESCC integrating both pathological image features and clinical information of patients with ESCC thereby enhancing the level of individualized and precise treatment for ESCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None